自觉稿件写得不错，投的杂志也都发表过类似论文，可是连续多次投稿均被编辑直接拒稿。啥原因呢？
论文稿件很好、规范撰写、也投对了杂志，却被直接退稿，提示：很有可能是因为Cover Letter(投稿信)没有写好。
A，SCI论文投稿后，需要过三关：编辑初审、同行评议和作者回答审稿人/编辑问题。通过编辑初审从而送外审，是第一步；B，外审专家基本上都是无偿评审；所以编辑会尽可能减少同行评议专家的工作量；并且，SCI杂志编辑大都具有直接退稿权和最终决定权；C，面对大量投稿，编辑不太可能是投稿论文的小同行专家，他们需要重点根据Cover Letter来了解稿件基本信息。由此，大部分期刊在编辑初审阶段直接退稿率达50%以上；而编辑多会在5-15分钟以内作出“是否送外审”的决定。1)低级错误（编辑直接退稿主要原因中的前五条）绝对不能犯；2)在Cover Letter里表达清楚尤为关键。投稿Cover Letter，成为影响期刊编辑直接拒稿还是送外审的最重要因素。而现实中，Cover Letter却往往最容易被中国学者忽视。Cover Letter是给编辑看的，是投稿人为自己的稿件陈情游说的最好机会。想象一下，让你用3分钟说服编辑花更多时间了解你的稿件，并进而录用你的稿件，你会怎么表达？对，言简意赅、逻辑清晰地展现对方关心的问题：这项研究有创新性，并且方法学严谨可靠。正式称呼编辑的姓名（如果您知道编辑的名字），同时也给出您的联系信息。需要注意称谓，不要简单写Dear Editor，建议直呼其姓（主编或者负责某一领域的责任编辑）。第一段：说明稿件题目及作者姓名；你也可说明所提交稿件的类型（研究论文、综述、个案、comments、meta分析等）。第二段，主要研究内容，重点介绍研究的主要结果；给出研究意义。如果你之前发表过的文章与本稿件直接相关，可以提及该文章。这些内容多从摘要中进一步凝练。第三段，接上段或者用一个短段落来解释研究具体的创新或者亮点之处，以及为什么适合该期刊。切忌笼统地说，自己的稿件“是对该领域有意义的”或“新颖的”；而是应该强调该目标期刊的宗旨和范围声明中的具体方面。如果目标期刊偏临床，则必须强调文章在临床诊治的重要性；如果目标期刊偏基础，那么您应当更多说明文章如何与期刊主题的相关性。即使投稿文章并非绝对适合此目标期刊，也要确保提及宗旨和范围声明中的某些内容，并解释清楚您的文稿为何会让该期刊的读者感兴趣。第四段：最后，用简短段落结束投稿信，其中应包括下列各点（无编辑的排除条件）：
所有信息结合起来，投稿信应当让编辑确信，本稿件创新性好，值得考虑在其期刊上发表。投稿信的用语，可以比摘要或引言更文辞华丽、给人更深刻的印象；从而抓住编辑的注意力。
XXX XX (通讯作者英文名字。名在前、姓在后)Department of XXX, XXX University XXX Hospital （通讯作者的科室和单位）No. X XXX Road, Beijing, China, XXX (通讯作者单位地址，邮编)Tel: + 86 （XXX）XXXX-XXXX (通讯作者单位电话)Email: XXX@XXX.edu (通讯作者工作邮箱，尽可能用大学邮件；尽可能不要163等数字域名的邮箱)Dr. XXX XX (杂志编辑部主任或者部门编辑名字，建议从杂志上直接找最合适的编辑)
Editor-in-Chief (根据编辑的职位做修改)
XXX (杂志名，用斜体)August 08, 2018 (适用于美国杂志；对于欧洲杂志，则用：08 August 2018)On behalf of my co-authors, I am submitting the enclosed material “XXX” (论文的题目) for possible publication in XXX (杂志名，用斜体).In the present study, XXX was conducted. We found that XXX. Especially, we distinguished XXX. To our best knowledge, this is the first study to report XXX. And we found XXX. We believe that this research falls within the scope of XXX (杂志名，斜体) and would be of particular interest to readers of your journal. （这一段主要用来总结投稿文章的主要结果和亮点-highlight）The work has not been published previously and it is not under consideration for publication elsewhere. The submission was approved by all authors and none of the authors has any potential financial conflict of interest related to the manuscript.This manuscript has been edited and proofread by MedEditing LLC. Thank you very much for your attention and consideration.XXX M.D., Ph.D. (通讯作者及学位)Professor, Department of XXX, XXX (通讯作者的title和单位)I am pleased to submit an original research article entitled “Title” by First Author and Corresponding author for consideration for publication in the “Journal”.We previously uncovered a role for XXX in DNA repair in U.[引证], and this manuscript builds on our prior study to determine XXX.In the present study, we found that XXX cell line displayed significant growth inhibition after gene name knockdown, which possibly resulted from cell cycle arrest and cell apoptosis. As a potential transcriptional factor, @@@ may regulate the expression of cell cycle or apoptosis-related genes. We found that the reduction of @@@ expression significantly increased the expression of caspases and reduced the expression of ###. These latter three genes belong to the inhibitor of ### gene family and their protein products can prevent apoptotic cell death. We concluded that the @@@ gene silencing via XXX could be developed as a candidate for therapy of ### in the near future.（这一段主要用来总结投稿文章的主要结果和亮点 - 如：A基因调控B机制影响C疾病的D功能）We believe that this manuscript is appropriate for publication by the Journal because it… [关于与该期刊宗旨和范围的具体关联].
This manuscript has not been published and is not under consideration for publication elsewhere. We have no conflicts of interest to disclose. If you feel that the manuscript is appropriate for your journal, we suggest the following reviewers:Thank you for your consideration!
Sincerely,
Name, PhD
Professor, Department of Pathology
University of XXX
转自：Hanson临床科研
